Go to the lifesciencesreport site and read the article.........here is an excerpt......
TLSR: We saw StemCells Inc. (STEM:NASDAQ) CEO Martin McGlynn at the RegenMed conference talking about his company, which is dealing with spinal cord injury and lysosomal storage disorders with its HuCNS-SC adult stem cells of embryonic origin. Do you follow this company?
JK: I do. I admire the work that Martin McGlynn has done and, specifically, the investigators at the company—Dr. Stephen Huhn and Dr. Ann Tsukamoto. This company operates at the next level of cell therapy. When I talk about mesenchymal cells and the trophic effects, it's exciting. But when I talk about potentially pluripotent cells and the ability for cells to remyelinate a demyelinating disorder like Batten disease, or to impact dry macular degeneration, or to impact the outcome in spinal paralysis. . .we're talking about the next level of science.
While it's been painstakingly meticulous, with the science and evolution of the field taking a long time, the way that StemCells is going about its clinical trials and developing its product and its cell line has been brilliant. I think it is a true leader in the field. When we look central nervous system (CNS) disorders, we should look at companies like StemCells—and the way it is accomplishing its science—as the right way to do things.
TLSR: As you are aware, the StemCells' scientific model is different from other companies, where cells are used in a drug-like model for their paracrine effects. StemCells has shown, on autopsy, durable engraftment of the human neurons that have been implanted in the brains of children with lysosomal storage disorders. It is very interesting work.
JK: That's exactly right. And it's a very different business model as well. If you're paralyzed and you've lost all sensation, you could potentially regain some sensation
or maybe even regain some control (bladder control, for example) if treated with a StemCells product. That would have a huge impact on a patient's quality of life. This company is doing pioneering work.
Investors will see a lot of breakthroughs from companies like StemCells Inc. I don't follow Advanced Cell Technology Inc. (ACTC:OTCBB), but it is doing interesting work in dry age-related macular degeneration. We recently published a very comprehensive CNS overview report in the amyotrophic lateral sclerosis space (Lou Gehrig's disease), and on the companies working to develop therapies for these patients. It is going to be an exciting couple of years as these companies start to show efficacy and proof of concept in CNS disorders.